Skye Bioscience, Inc. (SKYE)
NCM · Healthcare · Biotechnology
$0.58
-5.64%
Closing price as of 2026-07-30 · Source: TEK2day Finance
Key Metrics
Market Cap
$20.4M
Shares Outstanding
35.1M
Exchange
NCM
Currency
USD
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.2M | -13.3M | -14.9M | -12.7M |
| Net Income | -17.6M | -12.8M | -14.4M | -12.5M |
| Diluted EPS | $-0.44 | $-0.32 | $-0.36 | $-0.32 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -12.1M | -13.7M | -36.4M | -58.2M |
| Net Income | -19.5M | -37.6M | -26.6M | -55.9M |
| Diluted EPS | $-8.77 | $-5.37 | $-0.73 | $-1.41 |